

Dr. Charles Frederick LeMaistre's Publications

A. Books, Chapters, and Reviews

1. LeMaistre CF, Edwards DP, Dressler LG, Lathan B, Mansel RE, McGuire WL: Studies with monoclonal antibodies to breast tumors. Proceedings of the International Workshop on Monoclonal Antibodies and Breast Cancer. Ceriani R.L. (ed.), Martin Nijhoff, Boston, pp. 80-88, 1985.
2. LeMaistre CF, McGuire WL: The endocrine control of breast cancer. Clinical Surgery International, Volume 10, Forbes J.F. (ed.), Churchill Livingstone, Edinburgh, pp. 32-47, 1986.
3. LeMaistre CF, McGuire WL: Progesterone receptor determinations: A refinement of predictive tests for hormone dependency of breast cancer. Estrogen and Antiestrogen Action: Basic and Clinical Aspects. Jordan V.C. (ed.), Univ. of Wisconsin Press, pp. 341-354, 1986.
4. Wolff SN, Phillips GL, Fay JW, LeMaistre CF, Herzig RH, Herzig GP: Treating advanced Hodgkin's with intensive chemotherapy and autologous bone marrow transplantation. Autologous Bone Marrow Transplantation: Proceedings of the Third International Symposium. Dicke KA, Spitzer G, and Jagannath S. (eds.) University of Texas M.D. Anderson Cancer Center Houston, pp. 231-236, 1987.
5. Herzig RH, Wolff SN, Fay JW, LeMaistre CF, Frei-Lahr D, Lowder JN, Phillips GL, Herzig GP: Treatment of advanced melanoma with high dose chemotherapy and autologous marrow transplantation. Autologous Bone Marrow Transplantation: Proceedings of the Third International Symposium. Dicke KA, Spitzer G, and Jagannath S. (eds.), University of Texas M.D. Anderson Cancer Center. Houston, pp. 531-536, 1987.
6. Wolff SN, Phillips GL, Fay JW, Giannone L, LeMaistre CF, Herzig R, Herzig GP: High-dose chemotherapy with autologous marrow transplantation for gliomas. Autologous Bone Marrow Transplantation: Proceedings of the Third International Symposium. Dicke KA, Spitzer G, and Jagannath S. (eds.) University of Texas M.D. Anderson Cancer Center. Houston, pp. 557-563, 1987.
7. Herzig RH, Fay JW, Herzig GP, LeMaistre CF, Wolff SN, Frei-Lahr D, Lowder SN, Strandjord S: Phase I-II studies with high dose Thio-TEPA and autologous marrow transplantation in patients with refractory malignancies. High Dose Thio-TEPA and Autologous Marrow Transplantation. Herzig GP (ed.) Park Row Publishers, pp. 17-23, 1987.
8. Wolff SN, Herzig RH, Herzig GP, Fay JW, Phillips GL, LeMaistre CF: High dose ThioTEPA with autologous bone marrow transplantation for metastatic malignant melanoma. High Dose Thio-TEPA and Autologous Marrow Transplantation. Herzig GP (ed.) Park Row Publishers, pp. 25-28, 1987.
9. Fay JW, Herzig RH, Herzig GP, Wolff SN, LeMaistre CF, and members of the NABMTG. High Dose Thio-TEPA and Autologous Marrow Transplantation. Herzig GP (ed.) Park Row Publishers, pp. 31-34, 1987.
10. Herzig RH, Phillips GL, Wolff SN, Fay JW, LeMaistre CF, Reece DE, Frei-Lahr D, Lowder JN, Herzig GP: Autologous marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma: Preliminary results using new conditioning regimens. Experimental Hematology Today, 1987.

11. Bailes JS, LeMaistre CF: Hematologic Disorders. *Manual of Internal Medicine: Diagnosis and Therapy*. Stein J.H. (ed.), Appleton and Lange, Norwalk, pp. 403-438, 1988.
12. LeMaistre CF, McGuire WL: Hormone dependent breast cancer. *Progressive Stages of Neoplastic Growth*. Kaiser H.E. (ed.), Alden Press (London), pp. 70-79, 1988.
13. Deisseroth A, LeMaistre CF: Bone marrow transplantation. *Textbook of Internal Medicine*. Kelley W.N. (ed.), JB Lippincott & Co., Philadelphia PA, pp. 1347-1352, 1989.
14. Gholson CF, LeMaistre CF, Levin B: Gastrointestinal problems after bone marrow transplantation. *Current Therapy in Gastroenterology and Liver Disease*. Bayless TS (ed.), B. C. Decker, Inc., Philadelphia PA, pp. 194-199, 1990.
15. Phillips G, Fay JW, Herzig RH, Lazarus H, LeMaistre CF, Wolff SN, Herzig G: Autologous bone marrow transplant conditioning regimens for non-Hodgkin's lymphoma. *Autologous Bone Marrow Transplantation, Proceedings of the 4th International Symposium*. KA Dicke, G Spitzer, S Jagannath, MJ Evinger-Hodges, (eds.), University of Texas M.D. Anderson Cancer Center, Houston, pp. 305, 1989.
16. Herzig RH, Wolff SN, Fay JW, LeMaistre CF, Frei-Lahr D, Bolwell BJ, Lowder JN, Phillips GL, Brown RA, Herzig GP: Treatment of advanced melanoma with high-dose chemotherapy and autologous bone marrow transplantation. *Autologous Bone Marrow Transplantation, Proc of the 4th International Symposium*. KA Dicke, G Spitzer, S Jagannath, MJ Evinger-Hodges (eds.) University of Texas M.D. Anderson Cancer Center. Houston, pp. 499, 1989.
17. Deisseroth A, Herst CV, Wedrychowski A, Sims S, Seong D, Johnson E, Yuan T, Romine M, Paskalis N, Emerson S, Feinberg A, Bao P, Huston L, Claxton D, Kornblau S, LeMaistre CF, Kantaijian H, Talpaz M, Reading C, Spitzer G: Novel approaches to the therapy of CML. *New Strategies in Bone Marrow Transplantation*. Gale R and Champlin R (eds.), pp. 126-131, 1991.
18. LeMaistre CF: The IL-2 receptor as a potential target for therapy of acute graft vs. host disease. *IBID*, pp. 295 - 301, 1991.
19. LeMaistre CF, McCaffrey R, Woodworth T, Strom TB, Nichols JC, Murphy JR: Interleukin-2 receptor targeted cytotoxic therapy: Phase I clinical studies of DAB486IL-2 fusion toxin in hematologic malignancies. In: *Bacteria Protein Toxins*. Witholt B. (ed.), Gustar Fisher, Verlag, 1992.
20. Spitzer G, Huan S, Hester J, Ventura G, Dunphy FR, LeMaistre F, Yau JC, Spinolo JA, Jagannath S, Wallerstein RO, Dicke KA. Modification of the absolute neutropenia after high dose therapy with growth factors and peripheral blood cells. *Autologous Bone Marrow Transplantation: Proceedings of the Fifth International Symposium, 1990*. Dicke KA, Armitage JO, Dicke-Evinger MJ, (eds.), The University of Nebraska Medical Center, Omaha, pp. 857-861, 1991.

21. Deisseroth A, Wedrychowski A, Seong D, Paslidis N, Romine M, Howard OMZ, Claxton D, Komblau S, Herst CV, Yuan T, Fu M, Hu M, Johnson E, Gao P, Huston L, Emerson S, Guba S, Kantaian H, Talpaz M, Zhang W, Champlin R, Spencer V, Andersson B, Yao J, Spitzer G, LeMaistre F, Wallerstein R, Huan S, Ellerson D, Luttrell R, Herrick M, Gooch G, Reading C. Integration of molecular biology and genetics with biological and chemotherapeutic approaches to the management of chronic myelogenous leukemia (CML). In: Autologous Bone Marrow Transplantation: Proceedings of the Fifth International Symposium, 1990. Dicke KA, Armitage JO, Dicke-Evinger MJ (eds.).
22. The University of Nebraska Medical Center, Omaha pp. 65-75, 1991. 22. Meneghetti CM, LeMaistre CF. Initial clinical experiences with an interleukin-2 fusion toxin (DAB486IL-2). Genetically Engineered Toxins, Frankel AE (ed.), Marcel Dekker, Inc., pp. 395-401, 1992.
23. LeMaistre CF: Review of immunotoxin therapy of cancer. *Oncology*. 7:80-83, 1993.
24. Salzman D, LeMaistre CF: Immunotoxin for the therapy of graft vs. host disease in immunoconjugate therapy of hematologic malignancies. Rosen T and Kuzel S. (eds.), p. 134-144, 1993.
25. Bachier C, Freytes CO, Salzman D, Castro J, Boldt D, Roodman GD, Craig F, Harris K, Wiesner A, LeMaistre CF: Outcome of Patients with Poor Risk High Grade Non-Hodgkin's Lymphoma Treated with Autologous Bone Marrow Transplantation. Proceedings of the Seventh International Symposium on Autologous Bone Marrow Transplantation, pp. 391-398, 1994.
26. Freytes CO, Bachier C, Salzman D, Castro J, Boldt D, Roodman GD, Craig F, Harris K, Sheridan-Leos N, Hilsenbeck S, LeMaistre CF: High Dose Chemotherapy with Stem Cell Rescue in Patients with Low Grade Lymphoma. Proceeding Seventh International Symposium on Autologous Bone Marrow Transplantation, pp. 365-372, 1994.
27. Jacobs CA, Shpall EJ, Ball ED, Champlin RE, LeMaistre CF, Holland HK, Saral R, Berenson RJ: A Prospective, Randomized Phase III Study Using the Cephate SC stem cell concentrator to isolate CD34+ hematopoietic progenitors for autologous marrow transplantation after high dose chemotherapy. Proceeding Seventh International Symposium of Autologous Marrow and Blood Transplantation, pp. 669-678, 1994.
28. LeMaistre CF. FAHCT Inspectors Training Session. *ISHAGE Telegraft* 3(3): 5, 1996.
29. Board of Directors of the Foundation for the Accreditation of Hematopoietic Cell Therapy, International Society for Hematotherapy and Graft Engineering, and American Society for Blood and Marrow Transplantation. Joint Position Paper On The Regulatory Approach To Hematopoietic Cell Components In The United States. *Journal of Hematotherapy* 6:91-92 (1997).
30. Carabasi M, Henslee-Downey PJ, Trappe ME. Monograph: Cytomegalovirus in bone marrow transplant: Management of the high-risk patient. LeMaistre CF (ed). 1997.
31. LeMaistre CF Timing of Transplant for Patients with Non-Hodgkin's Lymphoma. *Lymphoma Biology and Research* pp 2-3. October, 1998.

32. C. F. LeMaistre on "DAB₃₈₉IL-2 (ONTAK): A Novel Fusion Toxin Therapy for Lymphoma". *Clinical Lymphoma*, Vol.1 (2), 117, 2000.
33. C. F. LeMaistre. "Two Novel Therapies for the Treatment of Cutaneous T-Cell Lymphoma". *Clinical Lymphoma*, Vol. 1, Suppl. 1: S7, Nov. 2000.
34. C. Frederick LeMaistre. DAB₃₈₉IL-2 (ONTAK): Other Potential Applications. *Clinical Lymphoma*, Vol.1, Suppl. 1, S37-S40, 2000.
35. C. F. LeMaistre (guest ed.). "Introduction." *Bone Marrow Transplantation*, Vol. 27, Suppl. 2: S1, May 2001.
36. C. F. LeMaistre. "DAB₃₈₉IL-2 (ONTAK): Development and Therapeutic Applications". *Cytotoxins and Immunotoxins for Cancer Therapy: Clinical Applications*. 115:2005.
37. C. F. LeMaistre. Colony-Stimulating Factors in Stem Cell Mobilization and Posttransplantation Immune Recover. *Oncology Perspective*. January 2005.
38. Shaughnessy PJ, LeMaistre CF. "DAB₃₈₉IL-2 (ONTAK): "Development and Therapeutic Applications". In: Kwakami K, Aggarwak B, Puri R, eds. *Cytotoxins and Immunotoxins for Cancer Therapy: Clinical Applications*. CRC Press, 115:2005.

B. Papers Published

1. Scidenfeld SM, LeMaistre CF, Setiawan SM, Munford RS. Emphysematous pyelonephritis caused by candida tropicalis. *Journal of Infectious Diseases*. 146(4):569, 1982.
2. LeMaistre CF, Knight WA III. High dose chemotherapy with autologous marrow rescue in the treatment of resistant solid tumors. *Invest New Drugs*. 1:321-329, 1983.
3. Montgomery MT, Redding SW, LeMaistre CF. The incidence of oral herpes simplex virus infection in patients undergoing cancer chemotherapy. *Oral Surg, Oral Med, Oral Pathol*. 61:238-242, 1986.
4. Von Hoff D, Clark G, Weiss G, Marshall M, Buchole J, Knight W, LeMaistre CF. Use of in vitro dose response effects to select antineoplastics for high dose or regional administration regimens. *J Clinical Oncology*. 4:1827-1834, 1986.
5. LeMaistre CF. Bone scans in advanced breast cancer. *Drug Therapy*. 16(2):163-164, 1986.
6. LeMaistre CF, Edwards DP, Krolick K, McGuire WL. An immunotoxin cytotoxic for breast cancer cells in vitro. *Cancer Research*. 47:730-734, 1987.
7. Roodman G, LeMaistre CF, Clark G, Page C, Newcomb T, Knight W. CFU-GEMM correlate with neutrophil and platelet recovery in patients receiving autologous marrow transplantation after high dose melphalan chemotherapy. *Bone Marrow Transplantation*. 2:165-173, 1987.
8. Mackowiak PA and LeMaistre CF. Drug fever: A critical appraisal of conventional concepts. An analysis of 51 episodes diagnosed at two Dallas hospitals and 97 episodes reported in the English literature. *Ann Int Med*. 106(5):728-733, 1987.

9. McGuire WL, Herzig RH, LeMaistre CF, Peters WP. Autologous bone marrow transplantation in breast cancer. *Breast Cancer Res Treat.* 11(1):7-17, 1988.
10. Wolff SN, Herzig RH, Fay JW, LeMaistre CF, Frei-Lahr D, Lowder J, Bolwell B, Giannone L, Herzig GP. High-dose ThioTEPA with autologous bone marrow transplantation for metastatic malignant melanoma: Results of phase I and II studies of the North American Bone Marrow Transplantation Group. *J Clin Oncol.* 7(2):245-249, 1989.
11. Gholson CF, Yau JC, LeMaistre CF, Cleary KR. Steroid-responsive chronic hepatic graft versus-host disease without extrahepatic graft-versus-host disease. *Am J Gastroenterology.* 84(10):1306-1309, 1989.
12. Brunner LJ, Luke DR, Lautersztain J, William LA, LeMaistre CF, Yau JC. Single-dose cyclosporine pharmacokinetics in various biological fluids of patients receiving allogeneic marrow transplantation. *Ther Drug Monit.* 12(2):134-138, 1990.
13. Yau JC, LeMaistre CF, Zagars GK, Williams LA, Meneghetti CK, Luke DR, Dunphy FR, Spinolo JA, Jagannath S, Spitzer G, Zander AR, Dicke KA. Methylprednisolone, cyclosporine and methotrexate for prophylaxis of acute graft-versus-host disease. *Bone Marrow Transplantation.* 5:269-272, 1990.
14. Ventura GJ, Barlogie B, Hester JP, Yau JC, LeMaistre CF, Wallerstein RO, Spinolo JA, Dicke KA, Horwitz LH, Alexanian R. High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support for refractory multiple myeloma. *Bone Marrow Transplantation.* 5:265-268, 1990.
15. Wolff SN, Herzig RH, Fay JW, LeMaistre CF, Brown RA, Frei-Lahr D, SutrdJorsd S, Giannone L, Herzig GD. High-dose *N, N'N''* Triethylenethiophosphomide (thiotepa) with autologous bone marrow transplantation: Phase I studies. *Seminars in Oncology.* 17:2-6, 1990.
16. Luke DR, Beck JE, Vadieli K, LeMaistre CF. Longitudinal study of cyclosporine and lipids in patients undergoing bone marrow transplantation. *J Clin Pharm.* 30(2):163-9, 1990.
17. Byers VS, Henslee PJ, Kernan NA, Blazar BR, Gingrich R, Phillips GL, LeMaistre CF, Gilland G, Antin JH, Martin P, Tutscha PJ, Trown P, Ackerman SK, O'Reilly RJ, Scannon RJ. Use of an anti-pan T-lymphocytic A chain immunotoxin in steroid resistant acute graft vs. host disease. *Blood.* 75(7):1426-1432, 1990.
18. Jagannath S, Barlogie B, Dicke K, Alexanian R, Zagars G, Cheson B, LeMaistre CF, Smallwood L, Pruitt K, Dixon DQ. Autologous bone marrow transplantation in multiple myeloma: Identification of prognostic factors. *Blood.* 76(9):1860-1866, 1990.
19. Spitzer G, Deisseroth A, Ventura G, Jagarmath S, Fogel B, Taylor K, Huan S, Dunphy F, Dicke K, Souza L, Yau J, LeMaistre CF, Spinolo J. Use of recombinant human hematopoietic growth factors and autologous bone marrow transplantation to attenuate the neutropenic trough of high-dose therapy. *Int J Cell Cloning.* 8:249-261, 1990.
20. LeMaistre CF, Herzig R. Mitoxantrone: Potential for use in intensive therapy. *Seminars in Oncology.* 17:43-48, 1990.
21. Luke J, Luke DR, Williams LA, LeMaistre CF, Yau JC. Prevention of cyclosporine-induced nephrotoxicity with clonidine. *J Clin Pharmacy.* 9(1):49-53, 1990.

22. LeMaistre CF, Yau JC. Allogeneic bone marrow transplantation in the treatment of hematologic malignancy. *Cancer Bulletin*. 43(3):131-135, 1990.
23. Wallerstein R, Spitzer G, Dunphy F, Huan S, Hortobagyi G, Yau J, Buzdar A, Holmes F, Theriault R, Ewer M, LeMaistre CF, Deisseroth A. A phase II study of mitoxantrone, etoposide (VP16), and thiotepa (MVT) with autologous marrow support for patients with relapsed breast cancer. *J Clin Oncol*. 8(11):1782-1788, 1990.
24. Herzig RH, Brown RA, Fay JW, Wolff SN, LeMaistre CF, Frci-Lahr D, Strandjord SE, Bolwell BJ, Giannone L, Coccia PF, Weick JK, Rothmann SA, Krupp KR, Lowder JN, Herzig GP. Phase I-II studies of high dose N,N,N" - triethylene thiophosphoramidate and autologous marrow transplantation in patients with refractory malignancies. *Cancer Therapy & Control*. 1: 141-153, 1990.
25. LeMaistre CF, Rosenblum MG, Reuben JM, Parkinson DP, Meneghetti CM, Parker K, Shaw JP, Deisseroth AB, Woodworth T. Therapeutic effects of a genetically engineered toxin (DAB486IL-2) in a patient with chronic lymphocytic leukemia. *Lancet*. 337:1124-25, 1991.
26. Reece DE, Barnett MJ, Connors JM, Fairey RN, Fay J, Grees JR, Herzig GP, Herzig R, Klingemann HG, LeMaistre CF, O'Reilly SE, Shepherd JP, Spinelli JJ, Voss NJ, Wolff SN, Phillips GL. Intensive chemotherapy with Cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. *J Clinical Oncology*. 9:1871-1879, 1991.
27. Huan SD, Dunphy FR, Yau JC, Dicke K, Spencer V, Wallerstein RO, LeMaistre CF, Andersson BS, Deisseroth AB, Hortobagyi GN, Holmes FA, Spitzer G. Impact of autologous bone marrow infusion on the hematopoietic recovery following high dose cyclophosphamide, etoposide, and cisplatinium. *J Clinical Oncology*. 9(9):1609-1617, 1991.
28. Cobb P, Jackson L, LeMaistre CF. Clinical application of immunotoxin therapy. *Cancer Bulletin*. 43(3): 233-239, 1991.
29. LeMaistre CF, Rosen S, Frankel A, Kornfeld S, Saria E, Meneghetti C, Drajesk J, Fishwildy D, Scannon P, Byers V. Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. *Blood*. 78(5):1173-1182, 1991.
30. Yau JC, Dirnopoulos NU, Huan SD, Spencer V, Woo SY, Spitzer G, Brunner LJ, Wallerstein RO, Deisseroth AB, Andersson BS, LeMaistre CF. An effective acute graft-vs.-host disease prophylaxis with minidose methotrexate, cyclosporine and single-dose methylprednisolone. *Am. Journal of Hematology*. 38:288-292, 1991.
31. Yau JC, Brunner U, Lopez-Berestein G, LeMaistre CF, Luke DR. Therapeutic drug monitoring of cyclosporine-lipoprotein levels. *Pharmacotherapy*. 11(4):291-295, 1991.
32. Yau JC, Dimopoulos MA, Huan SD, Tarrand JJ, Andersson BS, Spencer V, Spitzer G, Wallerstein RO, Meneghetti CM, LeMaistre CF. Prophylaxis with ganciclovir in allogeneic marrow transplantation. *Eur J Hematology*. 47:371-376, 1991.

33. Kantaijian HM, Talpaz M, LeMaistre CF, Spinolo J, Spitzer G, Yau J, Dicke K, Jagganath S, Deisseroth AB. Intensive combination chemotherapy and autologous bone marrow transplantation leads to reappearance of Philadelphia chromosome - negative cells in chronic myelogenous leukemia. *Cancer*. 67(12): 2959-2965, 1991.
34. LeMaistre CF, Rosenblum MG, Reuben JM, Parkinson DP, Meneghetti CM, Parker K, Shaw JP, Deisseroth AB, Woodworth T. Phase I trial of DAB486IL-2 in IL-2 receptor expressing malignancies. *Blood*. 79:2547-2554, 1992.
35. Cobb PW, LeMaistre CF. Therapeutic use of immunotoxins. *Seminars in Hematology*. 29:6-13, 1992.
36. Huan SD, Hester J, Spitzer G, Yau JC, Dunphy FR, Wallerstein RO, Dicke K, Spencer V, LeMaistre CF, Andersson BS, Deisseroth AB, Ventura GJ. Influence of mobilized peripheral blood cells in the hematopoietic recovery by autologous marrow and recombinant human granulocyte macrophage colony-stimulating factor after high-dose cyclophosphamide, etoposide and cisplatin. *Blood*. 79(12): 3388-3393, 1992.
37. Slichemnyer WJ, LeMaistre CF, Von Hoff DD. Response of metastatic adenoid cystic carcinoma and merkel cell tumor to high-dose melphalan with autologous bone marrow transplantation. *Investigational New Drugs*. 10:45-48, 1992.
38. Yau JC, LeMaistre CF, Andersson BS, Huan SD, Wallerstein RO, Woo SY, Spitzer G, Spinolo J, Spencer V, Brunner LJ, Dimopoulos MA, Jagganath S, Giralt S, Dicke KA, Deisseroth AB. Allogeneic bone marrow transplantation for hematologic malignancies following etoposide, cyclophosphamide, and fractionated total body irradiation. *Am J Hematology*. 41(1):40-44I, 1992.
39. Meneghetti C, LeMaistre CF: Initial experiences with an interleukin-2 fusion toxin. *Targ Diagn Ther*. 7:395-401, 1992.
40. Eckardt JR, Roodman GD, Boldt DH, Clark GM, Alvarez RR, Page C, Gaskill HI, LeMaistre CF: Comparison of engraftment and acute GVHD in patients undergoing cryopreserved or fresh allogeneic BMT. *Bone Marrow Transplantation*. 11:125-131, 1993.
41. Blume KG, Kopecky KJ, Henslee-Downey JP, Forman SJ, Stiff PJ, LeMaistre CF, Applebaum FR. A prospective randomized comparison of total body irradiation - etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with recurrent leukemia: A Southwest Oncology Group Study. *Blood*. 81(8):2187-2193, 1993.
42. Adkins D, Encarnacion C, Salzman D, Boldt D, Freytes C, Von Hoff DD, LeMaistre CF: Case Report: Durable complete remission in a patient with refractory mediastinal nonseminomatous germ cell tumor after tandem high dose chemotherapy and autologous bone marrow transplantation. *Bone Marrow Transplantation*. 12:541-546, 1993.
43. Adkins DR, Irvin R, Kuhn J, Boldt DH, Roodman GD, Salzman D, Freytes C, Von Hoff DD, LeMaistre CF: A Phase I trial of dacarbazine with autologous bone marrow transplantation in patients with solid tumors. *Investigational New Drugs*. 11:169-179, 1993.

44. LeMaistre CF, Craig FE, Meneghetti C, McMullin B, Parker K, Reuben J, Boldt DH, Rosenblum M, Woodworth T. Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematologic malignancies. *Cancer Research*. 53:3930-3934, 1993.
45. Bowers C, Adkins D, Dunphy F, Harrison B, LeMaistre CF, Spitzer G. Dose escalation of mitoxantrone given with thiotepa and autologous bone marrow transplantation for metastatic breast cancer. *Bone Marrow Transplantation*. 12(5):525-530, 1993.
46. Przepiorka D, LeMaistre CF, Huh YO, Luna M, Saria EA, Brown CT, Champlin RE. Evaluation of anti-CD5 ricin: A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation. *Therapeutic Immunol*. 1(2):77-82, 1994.
47. Saez R, Dahlberg S, Appelbaum FR, Fisher R, LeMaistre CF, Coltman CA. Autologous bone marrow transplantation in adults with non-Hodgkin's lymphoma: A Southwest Oncology Group Study. *Hematological Oncology*. 12:75-85, 1994.
48. Adkins DR, Salzman D, Boldt D, Kuhn J, Irvin R, Roodman GD, Lyons R, Smith L, Freytes CO, LeMaistre CF. A phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem cell transplantation in patients with lymphoma and multiple myeloma. *J Clin Oncology*. 12(9):1890-1901, 1994.
49. Giralt SA, LeMaistre CF, Vriesendorp FM, Anderson BS, Dimopoulos M, Gajewski J, Van Besien K, Mehra R, Przepiorka D, Khouri I, Yau J, Kantarjian H, Deisseroth AB, Champlin RE. Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies. *J Clin Oncology*. 12(9):1923-1930, 1994.
50. Morstyn G, Glaspy J, Shpall EJ, LeMaistre F, Briddell R, Menchaca D, Lill M, Jones R, Tami J, Brown S, Yan X, McNiece I. Clinical applications of filgrastim and stem cell factor in vivo and in vitro. *Journal of Hematotherapy*. 3:353-355, 1994.
51. Dimopoulos MA, Yau JC, Huan SD, Jagannath S, Spitzer G, Spinolo JA, Zagars GK, LeMaistre CF, Dicke KA, Zander AR. Allogeneic bone marrow transplantation for leukemia following piperazinedione and fractionated total body irradiation. *Am. J. Hematol*. 46(2):82-86, 1994.
52. Bachier CR, LeMaistre CF. Immunotoxin therapy of cancer: Rationale for development and future potential. *Clin. Immunother*. 3(6):450-460, 1995.
53. Van Besien K, Demuyneck H, LeMaistre CF, Bogaerts MA, Champlin R. High-dose melphalan allows durable engraftment of allogeneic bone marrow. *Bone Marrow Transplantation*. 15(2):321-323, 1995.
54. LeMaistre CF, Meneghetti C, House L, Osborne CK. Targeting the EGF receptor in breast cancer treatment. *Breast Cancer Res Treat*. 32 (1):97-104, 1994.
55. Van Besien K, Alexanian R, LeMaistre CF, Champlin R. Melphalan/Busulfan as conditioning regimen for allogeneic bone marrow transplantation. *Bone Marrow Transplantation*. 15(2):321-3, 1995.

56. Van Besien K, Tabocoff J, Rodriguez M, Andersson B, Mehra R, Przepiorka D, Dimopoulos M, Giralt S, Suki S, Khouri I, Spitzer G, Jagannath S, Dicke K, LeMaistre CF, Deisseroth A, Cabanillas F, Champlin RE. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplant for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. *Bone Marrow Transplantation*. 15(4):549-555, 1995.
57. Salzman D, Adkins DR, Craig F, Freytes C, LeMaistre CF. Malignancy associated pulmonary veno-occlusive disease: Report of a case following autologous bone marrow transplantation and review. *Bone Marrow Transplantation*. 18(6):775, 1996.
58. Vose JM, Pandite AN, Beveridge RA, Geller RB, Schuster MW, Anderson JE, LeMaistre CF, Ahmed T, Granena A, Keating A, Fernandez Ranada JM, Stiff PJ, Tabbara I, Longi W, Copelan EA, Nichols C, Smith A, Topolsky DL, Bierman PJ, Lebsack ME, Lange M, Garrison L. Granulocyte-Macrophage Colony-Stimulating Factor/Interleukin-3 Fusion Protein Versus Granulocyte-Macrophage Colony-Stimulating Factor After Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma: Results of a Randomized Double-Blind Trial. *Journal of Clinical Oncology*. 15(4): 1617-1623, 1997.
59. Nichols J, Foss F, Kuzel TM, LeMaistre CF, Platanius L, Ratain MJ, Rook A, Saleh M, Schwartz G. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. *Eur J. Cancer*. 33(Suppl 1):S34-S36, 1997.
60. Glick H, Shpall E, LeMaistre CF, McCarron T, Lu ZJ, Erder MH, Glaspy JA. Empirical Criteria for the Selection of Quality-of-Life Instruments for the Evaluation of Peripheral Blood Progenitor Cell Transplantation. *International Journal of Technology Assessment in Healthcare*. 14(3):419-430, 1997.
61. Glaspy JA, Shpall EJ, LeMaistre CF, Briddell RA, Menchaca DM, Turner SA, Lill M, Chap L, Jones Wiers MD, Sjeridan WP, McNiece I. Peripheral blood progenitor cell mobilization utilizing stem cell factor in combination with filgrastim in breast cancer patients. *Blood*. 90(8):2939-2851, 1997.
62. Shpall EJ, LeMaistre CF, Holland K, Ball E, Jones RB, Saral R, Jacobs C, Heimfeld S, Berenson R, Champlin R. A Prospective Randomize Trial of Buffy Coat versus CD34-Selection Autologous Bone Marrow Support in High-Risk Breast Cancer Patients Received High-Dose Chemotherapy. *Blood*. 90(11): 4313-4320, 1997.
63. LeMaistre CF, Saleh MN, Kuzel TM, Foss F, Plantanius LC, Schwartz G, Ratain M, Rook A, Freytes CO, Craig F, Reuben J, Nichols JC. Phase I Trial of a Ligand Fusion-Protein (DAB₃₈₉IL-2) in Lymphomas Expressing the Receptor for Interleukin-2. *Blood*. 91(2):399-405, 1998.
64. Saleh MN, LeMaistreCF, Kuzel TM, Foss F, Platanius LC, Schwartz G, Ratain M, Rook A, Freytes C, Craig F, Reuben J, Sams MW, Nichols J. Antitumor Activity Of DAB389IL-2 Fusion Toxin In Mycosis Fungoides. *J Am Acad Dermatol*. 39(1): 63-73, 1998.
65. Shpall EJ, Wheeler CA, Turner SA, Yanovich S, Brown RA, Pecora AL, Shea TC, Mangan KF, Williams SF, LeMaistre CF, Long GD, Jones R, Davis MW, Murphy-Filkins R, Parker WRL, Glaspy JA. A Randomized Phase 3 Study of Peripheral Blood Progenitor Cell Mobilization with Stem Cell Factor and Filgrastim In High-Risk Breast Cancer Patients. *Blood*. 93(8):2491-2501, 1999.

66. Gokmen E, Bachier C, Raaphorst FM, Muller TE, Armstrong RD, LeMaistre CF, Teale JM. Ex-Vivo Expansion of Bone Marrow Progenitor Cells for Hematopoietic Reconstitution Following High-Dose Chemotherapy for Breast cancer. *Exp Hematol.* 27(4):615-23, 1999.
67. Stiff P, Gingrich R, Luger S, Wyres MR, Brown RA, LeMaistre CF, Perry J, Schenkein DP, List A, Mason JR, Besinger W, Wheeler C, Freter C, Parker WRL, Emmanouilides C. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma. *Bone Marrow Transplantation.* 26(5):471-481, 2000.
68. Wolff SN, Fay J, Stevens D, Herzig RH, Pohlman B, Bolwell B, Lynch J, Freytes C, LeMaistre F, Collins R, Pineiro L, Greer J, Stein R, Goodman SA, Dummer S. Fluconazole versus Low-Dose Amphotericin B for the Prevention of Fungal Infections in Patients Undergoing Bone Marrow Transplantation: a Study of the North American Marrow Transplant Group. *Bone Marrow Transplantation.* 25(8):853-859, 2000.
69. Nieto Y, Champlin R, Wingard J, Vrendenburgh J, Elias A, Richardson P, Glaspy J, Jones RB, Stiff P, Bearman SI, Cagnoni PJ, McSweeney PA, LeMaistre CF, Pecora A, Shpall EJ. Status of High Dose Chemotherapy for Breast Cancer: A Review. *Biology of Blood and Marrow Transplantation.* 6:476-495, 2000.
70. LeMaistre CF. DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential applications. *Clin Lymphoma.* Suppl 1:S37-40, 2000.
71. LeMaistre CF. Two novel therapies for the treatment of cutaneous T-cell lymphoma. *Clin Lymphoma.* Suppl 1:S7, 2000
72. Shaughnessy PJ, Ririe DW, Ornstein DL, Kissack B, Bickford DJ, Molina R, Lanzkron S, Bachier C, Nanez A, LeMaistre CF. Graft Failure in a Patient with Systemic Lupus Erythematosus (SLE) Treated with High-Dose Immunosuppression and Autologous Stem Cell Rescue. *Bone Marrow Transplantation.* 27: 221-224, 2001.
73. Gokmen E, Bachier C, Raaphorst F M, Muller T, Armstrong D, LeMaistre CF, Teale J M. Ig heavy chain CDR3 size diversities are similar after conventional peripheral blood and ex vivo expanded hematopoietic cell graft transplants. *Bone Marrow Transplantation.* 27(4):413-424, 2001.
74. Lazarus HM, Loberiza FR, Zhang M-J, Armitage JO, Ballen KK, Bashey A, Bolwell BJ, Burns LJ, Freytes CO, Gale RP, Gibson J, Herzig RH, LeMaistre CF, Marks D, Mason J, Miller AM, Milone GA, Pavlovsky S, Reece DE, Rizzo JD, van Besien K, Vose JM, Horowitz MM: Autotransplants for Hodgkin's disease in first relapse remission: a report from the autologous blood and marrow transplant registry (ABMTR). *Bone Marrow Transplantation.* 24(4):387-396, 2001.
75. Lee SJ, Klein JP, Anasetti C, Antin J, Loberiza FR, Bolwell BJ, LeMaistre CF, Litzow MR, Marks D, Waller EK, Matlack M, Giral S, Horowitz MM: The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase. *Blood.* 98(12):3205-3211, 2001.

76. Pecora AL, Stiff P, LeMaistre CF, Bayer R, Bachier C, Goldberg SL, Parthasarathy M, Jennis AA, Smith AK, Douville J, Chen B, Armstrong RD, Mandalam RK, Preti R: A phase II trial evaluating the safety and effectiveness of the AastromReplicell system for augmentation of low-dose blood stem cell transplantation. *Bone Marrow Transplantation*, 28(3):295-303, 2001.
77. Spall E, Adkins D, Appelbaum F, Keating A, LeMaistre CF, Mangen K, Smith F council on Education and Standards, Task Force on Guidelines for Clinical Centers and Training: American Society for Blood and Marrow Transplantation guidelines for training. *Biology of Blood and Marrow Transplantation*. 7(10):577, 2001.
78. Gokmen E, Bachier C, Raaphorst F M, Muller T, Armstrong D, LeMaistre C F, Teale J M: Ex vivo expanded hematopoietic cell graft recipients exhibit T-cell repertoire diversity similar to that seen after conventional stem cell transplants. *J Hematother Stem Cell Res*. 10(1):53-66, 2001.
79. Shaughnessy PS, Ornsten D, Ririe D, Callander N, Anderson JE, Pollack MS, Freytes CO, Cruz J, Rodriguez T, Bachier C, LeMaistre CF: Phase II Study of a Moderate Intensity Preparative Regimen with Allogeneic Peripheral Blood Stem Cell Transplantation for Hematologic Diseases: The Texas Transplant Consortium Experience. *Biology of Blood and Marrow Transplantation*. 8:420-428, 2002.
80. Nash RA, Bowen JD, McSweeney PA, Pavletic ZS, Maravilla KR, Park MS, Sullivan KM, Al-Omaishi, J, Corboy JR, Derrington D, DiPersio J, Georges GE, Gooley TA, Holmberg LA, LeMaistre CF, Openshaw H, Ryan K, Sunderhaus J, Storb R, Storek J, Zunt J, Kraft G: High-dose Immunosuppressive Therapy and Autologous Stem Cell Transplantation for Severe Multiple Sclerosis. *Blood*. 102:2364-2372, 2003.
81. Nash RA, Andsey R, Storek J, Georges GE, Holmberg LA, Kraft G, Mayes MD, McDonagh K, Chen CS, DiPersio J, LeMaistre CF, Pavletic ZS, Sullivan KM, Sunderhaus J, Furst DE, McSweeney PA. Epstein-Barr Virus –Associated post-Transplant Lymphoproliferative Disorder After High-Dose Immunosuppressive Therapy and Autologous CD-34 Stem Cell Transplantation for Sever Autoimmune Diseases. *Biology of Blood and Marrow Transplantation*. 9(9):583-592, 2003.
82. Tallman MS, Gray R, Rober NJ, LeMaistre CF, Osborne CK, Vaughan WP, Gradishar WJ, Pisansky TM, Fetting J, Paietta E, Lazarus HM. Conventional Adjuvant Chemotherapy with or without High-Dose Chemotherapy and Autologous Stem Cell Transplantation in High-Risk Patients. *N Engl J Med*. 349(1):17-26, 2003.
83. 82. Vose JM, Rizzo JD, Tao-Wu J, Armitage JO, Bashey A, Burns LJ, Christiansen NP, Freytes CE, Gale RP, Gibson J, Giralt SA, Herzig RH, LeMaistre CF, McCarthy Jr PL, Nimer SD, Peterson FB, Schenkein DP, Wiernik PH, Wiley JM, Loberiza FR, Lazarus HM, von Biesen K, Horowitz MH. Autologous transplantation for Diffuse Aggressive non- Hodgkin's Lymphoma in First Relapse or Second Remission: A Report from the Autologous Blood and Marrow Transplant Registry (ABMTR). *Biology of Blood and Marrow Transplantation*. 10(2):116-127, 2004.
84. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramari T, Shea T, Yanovich S, Hansen K, Noga S, McCarty J, LeMaistre CF, Sung E, Blazar B, Elhardt D, Chen M, Emmanouilides C. Palifermin for Oral Mucositis after Intensive Therapy for Hematologic Cancers. *NEJM* 351:2590-8. 2004.

85. Loberiza FR, Lee SJ, LeMaistre CF, Eapen M, Rizzo JD, Zhang MJ, Klein JP, Serna DS, Horowitz MM. Association of Transplant Center and Physician Factors on Mortality after Stem Cell Transplantation in the United States. *Blood*.105(7):2979-87. 2005.
86. Shaughnessy PJ, Bachier C, Grimley M, Freytes CO, Callendar NS, Essell JH, Flomenberg N, Selby G, LeMaistre CF. Denileukin difitox for the treatment of steroid-resistant acute graft-versus-host disease. *Biology of Blood and Marrow Transplantation*. 11(3):188-193. 2005.
87. LeMaistre CF, Loberiza F. What is Quality in a Transplant Program? *Biology of Blood and Marrow Transplantation*. 11(4):241-246. 2005.
88. Gajewski JL, Simmons A, Weinstein R, Snyder E, McMannis J, Patashnik B, Hassenbusch S, LeMaistre CF, Woods R, Denman C, Silver S. The New Apheresis and Blood and Marrow Transplantation-related Current Procedural Terminology Codes for Payment of Apheresis and Blood and Marrow transplantation services. *Biology of Blood and Marrow Transplantation*. 11(11):871-80, 2005.
89. Shaughnessy PJ, Alexander W, Tran H, Ririe D, Splichal J, Pollack M, Bachier C, LeMaistre CF. Phase I and Pharmacokinetic Study of Once Daily Dosing of Intravenous Busulfan in the Setting of a Reduced Intensity Preparative Regimen and Allergenic Hematopoietic Stem Cell Transplantation as Immunotherapy for Renal Cell Carcinoma. *Mil Med*. 171(2):000, 2006.
90. Shaughnessy PJ, Bachier C, LeMaistre CF, Akay C, Pollock BH, Gazitt Y. Granulocyte Colony-Stimulating Factor Mobilizes More Dendritic Cell Subsets Than Granulocyte-Macrophage Colony-Stimulating Factor with No Polarization of Dendritic Cell Subsets in Normal Donors. *Stem Cells* 24(7):1789-1797, 2006.
91. Jones RB, Anasetti C, Appel P, DiPersio J, Heslop H, LeMaistre F, Silver S, Sirilla J, Stiff P. Committee on Hematopoietic Cell Therapy Quality Outcomes. ASBMT Committee Report; White paper on measurement of quality outcomes. *Biology of Blood and Marrow Transplantation*. 12(5):594-7, 2006.
92. Pavletic S., Zhou G., Sobocinski K., Marti G., Doney K., DiPersio J., Feremans W., Foroni L., Goodman S., Prentice G., LeMaister C., Bandini G., Ferrant A., Jacobsen N., Khouri I., Gale R., Wiestner A., Giralto S., Montserrat E., Chan W., Bredeson C. Genetically-Identical Twin Transplants for B-cell Chronic Lymphocytic Leukemia and Evidence for Type 1 Donor Cell Derived Leukemia. *Leukemia*. 21(12): 2452-5. 2007 Dec.
93. Nash R, McSweeney P, Crofford L, Abidi M, Chen CS, Godwin JD, Gooley T, Holmberg L, Henstorf G, LeMaistre CF, Mayes M, McDonagh K, McLaughlin B, Molitor J, Nelson JL, Shulman H, Storb R, Viganego F, Wener M, Seibold J, Sullivan K, Furst D. – High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Severe Systemic Sclerosis: Long-Term Follow-Up of the U.S. Multicenter Pilot Study. *Blood*. 110(4): 1388-96; 2007 Aug.
94. Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell B, Bredeson CN, Burns LJ, Cairo MS, Freytes CO, Goldstein SC, Hale GA, Inwards DJ, LeMaistre CF, Maharaj D, Marks DI, Schouten HC, Slavin S, Vose JM, Lazaruz HM, Besien Kv. - Allogeneic Transplants in Follicular Lymphoma: Higher Risk of Disease Progression after Reduced Intensity Compared to Myeloablative Conditioning. *Biology of Blood and Marrow Transplantation*. 14(2):236-45, 2008 Feb.

95. Lazarus HM, Carreras J, Boudreau C, Loberiza FR, Armitage JO, Bolwell BJ, Freytes CO, Gale RP, Gibson J, Hale GA, Inwards DJ, LeMaistre C, Maharaj D, Marks DI, Miller AM, Pavlovsky S, Schouten HC, Besien K, Vose JM, Rizzo JD – Influence of Age and Histology on Outcome in Adult Non-Hodgkin’s Lymphoma Patients undergoing Autologous HCT: A Report from the Center for International Blood & Marrow Transplant Research (CIBMTR) – 2008. *Biology of Blood and Marrow Transplantation*. 14(12):1323-1333, 2008.
96. Membreno FE, Ortiz J, Foster PF, Wright F, Ostrower VS, Metter JD, Palma-Vargas J, LeMaistre CF. Liver transplantation for sinusoidal obstructive syndrome (veno-occlusive disease): case report with review of the literature and the UNOS database. *Clin Transplant*.22 (4):397-404, 2008 Jul-Aug.
97. LeMaistre CF. Defining Medicare Coverage for MDS treatment and research: a time for action? *Biology of Blood and Marrow Transplant*. 15(2):133-4. 2009
98. Gajewski JL, LeMaistre CF, Silver SM, Lill, MC, Selby GB, Horowitz MM, Rizzo JD, Heslop HE, Anasetti C, Maziarz RT. *Biology of Blood and Marrow Transplant*. 15(12):1493-501. 2009.
99. Baker KS, Davies SM, Majhail NS, Hassebroek A, Klein JP, Ballen KK, Bigelow CL, Frangoul HA, Hardy CL, Bredeson C, Dehn J, Friedman D, Hahn T, Hale G, Lazarus HM, LeMaistre CF, Loberiza F, Maharaj D, McCarthy P, Setterholm M, Spellman S, Trigg M, Maziarz RT, Switzer G, Lee SJ, Rizzo JD. Race and Socioeconomic Status Influence Outcomes of Unrelated HCT. *Biology of Blood and Marrow Transplantation*. 15(12)1543-54, 2009.
100. Loberiza Jr FR, Lee SJ, Klein JP, Hassebroek A, Dehn JG, Frangoul HA, Hahn T, Hale G, Lazarus HM, LeMaistre CF, Maziarz RT, Rizzo JD, Majhail NS. Outcomes of Hematological Malignancies after Unrelated Donor Hematopoietic-Cell Transplantation According to Place of Residence. *Biology of Blood and Marrow Transplantation*. 16(3):368-75, 2010.
101. Hari PN, Majhail NS, Zhang MJ, Hassebroek A, Siddiqui F, Ballen K, Bashey A, Bird J, Freytes CO, Gibson J, Hale G, Holmberg L, Kamble R, Kyle RA, Lazarus HM, LeMaistre CF, Loberiza F, Maiolino A, McCarthy PL, Omondi N, Reece D, Seftel M, Trigg M, Vesole D, Weiss B, Wiernik P, Lee SJ, Rizzoo JD, Mehta P. Race and Outcome of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. *Biology of Blood and Marrow Transplantation* 16(3):395-402. 2010.
102. LeMaistre JA, Bachier CB, Smith B, LeMaistre CF, Shaughnessy PJ Once daily busulfan and cyclophosphamide is well tolerated and effective as a preparative regimen for allogeneic hematopoietic stem cell transplant. *J Oncol Pharm Pract* 2011 Jan 12 (epub ahead of print).
103. Race/Ethnicity and Survival after Single Umbilical Cord Blood Transplantation for Adults and Children with Leukemia and Myelodysplastic Syndromes. Submitted NEJM April, 2011.